In Depth 16 Nov 2023
Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again
Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […]